Associate Professor, Dermatology, Perelman School of Medicine
Dermatology
Dr. Joel M. Gelfand, MD
|
|
Give Review
Joel Gelfand is an expert in the field of Dermatology. He graduated from Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received awards:"CMS Meaningful Use Stage 1 Certification", "Fellow (FAAD)" and "Super Doctor". Joel M. Gelfand, MD is a published physician as well. He has 100 publications published. The latest was: Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery Wit... Joel Gelfand is registered with Medicare.
Publications
- Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery Wit...
- Response to 'Kidney disease in moderate-to-severe Psoriasis: a critical appraisal'.
- Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque Psoriasis.
- Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3.
- Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.
- Risk of major cardiovascular events in patients with psoriatic arthritis, Psoriasis and rheumatoid arthritis: a population-based cohort study.
- Effect of Psoriasis Severity on Hypertension Control: A Population-Based Study in the United Kingdom.
- Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe Psoriasis in the clinical setting.
- OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of Psoriasis final 5-year results.
- Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network.
- Patient-reported outcomes for psoriasis patients with clear versus almost clear Skin in the clinical setting.
- Retrospective Analysis of Beta-Blocker Instituted for Treatment of Hemangiomas (RABBIT Study).
- Palmoplantar Psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque Psoriasis.
- High-density lipoprotein cholesterol function improves after successful treatment of Psoriasis: a step forward in the right direction.
- Reliability and Validity of Mobile Teledermatology in Human Immunodeficiency Virus-Positive Patients in Botswana: A Pilot Study.
- Counterpoint: A tale of two meta-analyses revisited.
- Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors.
- Patient Satisfaction with Treatments for Moderate-to-Severe Plaque Psoriasis in Clinical Practice.
- Diabetes incidence in psoriatic arthritis, Psoriasis and rheumatoid arthritis: a UK population-based cohort study.
- Research gaps in Psoriasis: Opportunities for future studies.
- Product of the Physician Global Assessment and body surface area: A simple static measure of Psoriasis severity in a longitudinal cohort.
- Psoriasis Severity and the Prevalence of Major Medical Comorbidity: A Population-Based Study.
- Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.
- Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses.
- Validity of diagnostic codes and prevalence of Psoriasis and psoriatic arthritis in a managed care population, 1996-2009.
- Evaluation of AJCC tumor staging for cutaneous squamous Cell carcinoma and a proposed alternative tumor staging system.
- Psoriasis and psoriatic arthritis: a public health agenda.
- Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe Psoriasis.
- OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of Psoriasis.
- Prevalence and treatment patterns of psoriatic arthritis in the UK.
- Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and Psoriasis: a longitudinal cohort study.
- Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
- Aortic vascular inflammation in Psoriasis is associated with HDL particle size and concentration: a pilot study.
- Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe Psoriasis.
- Abnormal lipoprotein particles and cholesterol efflux capacity in patients with Psoriasis.
- Metabolic syndrome in patients with psoriatic disease.
- The impact of Psoriasis on 10-year Framingham risk.
- Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using 18-F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT).
- High Prevalence of Aquagenic Wrinkling of the Palms in Patients with Cystic Fibrosis and Association with Measurable Increases in Transepidermal Water Loss.
- Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque Psoriasis in the clinical practice setting.
- Consensus guidelines for the management of plaque Psoriasis.
- Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom.
- Reliability and validity of a photographic method for measuring facial hair density in men.
- Dermatologist response rates to a mailed questionnaire: a randomized trial of monetary incentives.
- Dermatologist preferences for first-line therapy of moderate to severe Psoriasis in healthy adult patients.
- HIV-positive patients in Botswana state that mobile teledermatology is an acceptable method for receiving dermatology care.
- High Clinical Response Rate of Sezary Syndrome to Immunomodulatory Therapies: Prognostic Markers of Response.
- Attributable risk estimate of severe Psoriasis on major cardiovascular events.
- The risk of Infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: AÂ systematic review and meta-analysis of rand...
- Systemic and Vascular Inflammation in Patients With Moderate to Severe Psoriasis as Measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomograp...
- Psoriasis and cardiovascular risk: strength in numbers, part II.
- Prevalence of the metabolic syndrome in Psoriasis: results from the national health and nutrition examination survey, 2003-2006.
- Guidelines of care for the management of Psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of Psoriasis and psoriatic arthritis: Case-b...
- Seeing red: flushing out instigators of niacin-associated Skin toxicity.
- The risk of depression, anxiety, and suicidality in patients with Psoriasis: a population-based cohort study.
- Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need.
- Diet and weight loss as a treatment for Psoriasis.
- Psoriasis and cardiovascular risk: strength in numbers.
- Assessing long-term drug safety: lessons (re) learned from raptiva.
- Guidelines of care for the management of Psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of Psoriasis with phototherapy and photoche...
- Complementary and alternative medicine for Psoriasis: a qualitative review of the clinical trial literature.
- The risk of stroke in patients with Psoriasis.
- Guidelines of care for the management of Psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of Psoriasis with traditiona...
- Guidelines of care for the management of Psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of Psoriasis with topical th...
- A prospective clinical trial of open-label etanercept for the treatment of Hidradenitis suppurativa.
- A randomized, double-blind comparison of the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine required for effe...
- Use of complementary and alternative medicine among adults with Skin disease: results from a national survey.
- The prevalence of previously diagnosed and undiagnosed Psoriasis in US adults: results from NHANES 2003-2004.
- Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of Basal cell and squamous cell carcinoma in patients undergoing Mohs micr...
- AJC editor's consensus: Psoriasis and coronary artery disease.
- Adverse drug events in infliximab-treated patients compared with the general and Psoriasis populations.
- Methicillin-resistant Staphylococcus aureus colonization in children with atopic Dermatitis.
- Psoriasis and metabolic disease: epidemiology and pathophysiology.
- Immunosuppressant medications and mortality in inflammatory bowel disease.
- The pitfalls of a purely clinical definition of nephrogenic systemic fibrosis: comment on the article by Todd et al.
- Patient-reported outcomes and health-care resource utilization in patients with Psoriasis treated with etanercept: continuous versus interrupted treatment.
- Oral curcumin in the treatment of moderate to severe Psoriasis vulgaris: A prospective clinical trial.
- From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for Psoriasis.
- Update on the natural history and systemic treatment of Psoriasis.
- The risk of mortality in patients with Psoriasis: results from a population-based study.
- Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in Psoriasis patients.
- Synthetic imidazoquinolines potently and broadly activate the Cellular immune response of patients with cutaneous T-Cell lymphoma: synergy with interferon-gamma enhanc...
- Long-term treatment for severe Psoriasis: we're halfway there, with a long way to go.
- The role of topical therapy for patients with extensive Psoriasis.
- Prevalence of cardiovascular risk factors in patients with Psoriasis.
- Risk of myocardial infarction in patients with Psoriasis.
- The epidemiology of sunburn in the US population in 2003.
- The risk of lymphoma in patients with Psoriasis.
- Prevalence and treatment of Psoriasis in the United Kingdom: a population-based study.
- CD8+ lymphoma in a patient with human immunodeficiency virus.
- Epidemiology of psoriatic arthritis in the population of the United States.
- Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
- Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
- Vitiligo-like hypopigmentation associated with imiquimod treatment of genital Warts.
- Adverse cutaneous reactions to guggulipid.
- The prevalence of Psoriasis in African Americans: results from a population-based study.
- Determinants of quality of life in patients with Psoriasis: a study from the US population.
- Progressive epidermotropic CD8+/CD4- primary cutaneous CD30+ lymphoproliferative disorder in a patient with sarcoidosis.
- Lymphoma rates are low but increased in patients with Psoriasis: results from a population-based cohort study in the United Kingdom.
Schools
Harvard Medical School
Mt Sinai School Of Med
University Of Pa Health System
Procedures Preformed
- Destruction of Benign Skin Lesion
- Destruction of Malignant Skin Lesion
Conditions Treated
- Acne
- Actinic Keratosis
- Basal Cell Carcinoma
- Benign Skin Lesion
- View All
Doctors Specialties
- Dermatology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Golden Rule
- HealthPartners
- Community Blue PPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- MagnaCare
- MedHealthInsurance
- Medicare MCR
- MultiPlan PPO
- Freedom Plan
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FAAD)
- Super Doctor
Education
-
University of Pennsylvania Health System -
Mount Sinai School of Medicine -
Harvard Medical School
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center -
Pennsylvania Hospital
Drug Facts
| NPI NUMBER | 1710902382 | |
| NPPES Provider LastName | GELFAND | |
| NPPES Provider FirstName | JOEL | |
| NPPES Provider ZIPCode | 19104 | |
| NPPES Provider State | PA | |
| Specialty Description | Dermatology | |
| Total Claim Count | 293.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710902382 |
| Last Name Of The Provider | GELFAND |
| First Name Of The Provider | JOEL |
| View All |
Similar Doctors
|
|
Amber Tran, MSN
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine Shaver, MD |
|
|
Myriam L. Gonzalez |
|
|
Kristen Foering |
|
|
Dr. Adam B. Blechman, MD |
|
|
Dr. Brian C. Capell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne M. Angeles, MD |
|
|
Dr. Emily Y. Chu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barry B. Abraham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Magdalene Y. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monica R. Boyle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence C. Parish, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Nazanin Saedi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven Fakharzadeh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Glen H. Crawford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James R. Treat, MD
This Doctor is OpenDoctor Recommended.
|